Pronova Hopes Rx Omega-3 Success Translates To Supplements
This article was originally published in The Pink Sheet Daily
Executive Summary
Pronova BioPharma ASA has the capabilities necessary to become “a major player in the new supplement market,” CEO Morten Jurs said. The Norwegian firm likely will spend $10 million to adjust its plant to manufacture consumer products and plans to enter the supplement market in the second half of 2012.
You may also be interested in...
Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?
Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.
Coalition Pushes Congress On OTC Purchases With Health Savings Accounts
The Health Choices Coalition sent letters urging House and Senate members to support legislation that would strike the health care reform law requirement that consumers obtain a prescription in order to purchase OTCs with a pre-tax savings account.
TheraBiogen Supports Theramax Expansion With Education Push
Homeopathic firm TheraBiogen plans to roll out products “every six to nine months” to add to its existing lineup of homeopathic remedies for allergy and cold and flu, says CEO Kelly Hickel. The firm also counts on sales growth from a social media campaign to explain what is not in its products as well as what is.